post-bg-569
calendary March 6, 2023

The first gene therapy drug for the treatment of hemophilia B

Hemophilia B is an inherited disease that results in a malfunction of the gene that regulates the synthesis of blood coagulation factor IX. As a result, patients suffer from bleeding, which is very difficult to stop. With hemophilia, the risk of death of a patient from a hemorrhage in the brain and other vital organs increases sharply, even with a minor injury.

Currently, hemophilia B is treated with replacement therapy (blood clotting factor IX is administered intravenously, in severe form several times a week). This type of therapy is quite effective but is associated with a large number of inconveniences for patients, and therefore the development of innovative drugs has is a relevant objective.

In 2022, the first gene therapy drug called Hemgenix was registered in the US. This drug is administered by infusion and is designed to replace the gene that codes for factor IX. Hemgenix uses a viral vector to deliver the gene to the liver, where it is taken up by cells and stimulates the production of clotting factor IX.

In the European Union, Hemgenix has been approved based on the results of the HOPE-B study. According to the results of the study, patients with hemophilia B treated with Hemgenix experienced a stable and prolonged increase in the average level of factor IX activity by 36.9 %, which resulted in a 64 % decrease in the adjusted annual bleeding rate.

In the US, Hemgenix costs $3.5 million. In Europe, the therapy could cost around $1 million, but the final price has not yet been announced.

It is worth noting that a gene therapy drug for the treatment of hemophilia B is also being developed in Russia. Research in this area is carried out by the Biocad company. Preclinical studies have now been completed in support of the first phase of clinical trials.

According to the Russian register for medicinal products, in February 2023, the first Phase I-II clinical trial (No. ANB-002-1/SAFRAN "An open-label non-comparative study of the safety, pharmacodynamics and efficacy of ANB-002 in a single dose in increasing doses in patients with hemophilia B") started. Completion of the study is scheduled for 2031. 54 patients will take part in it.

References:
  1. https://www.ehc.eu/ru/
  2. europa.eu/en/medicines/human/summaries-opinion/hemgenix
  3. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b
  4. https://www.vademec.ru/news/2022/09/27/biokad-provedet-ki-genoterapevticheskogo-preaparata-ot-gemofilii-/

More related posts

new-img-1

Control

Fine for spa resort in Yessentuki

Roszdravnadzor has imposed a fine of 130 thousand rubles on a spa resort in Yessentuki for improper storage of medical products…

03.03.2016
READ ARTICLE
new-img-2

Roszdravnadzor

Roszdravnadzor – patients’ rights

In 2015, Roszdravnadzor restored the rights of more than 460 thousand citizens to effective, accessible, and safe medical…

03.03.2016
READ ARTICLE
new-img-3

Regulation

The certification scheme for medical products hasn’t changed recently

Roszdravnadzor informs that the certification scheme for products in the Russian Federation is determined by Decree of the…

03.04.2016
READ ARTICLE
new-img-4

Control

Fines – Rostov region

In one and a half months of 2016, the Local Agency of Roszdravnadzor in Rostov Region imposed fines of the total amount of…

03.10.2016
READ ARTICLE
new-img-5

Control

Unregistered medical products

Two citizens were fined for selling unregistered medicinal products on the Internet in the Republic of Bashkortostan.

03.10.2016
READ ARTICLE
new-img-6

Control

Unscheduled inspection by roszdravnadzor

Roszdravnadzor started an unscheduled inspection of the Federal State-Funded Institution of Sverdlovsk Region Kirovgrad Central…

03.14.2016
READ ARTICLE
new-img-7

Medical Devices

International medical device regulators forum (IMDRF)

The delegation of the Federal Service for Surveillance in Healthcare headed by Mikhail Murashko, Head of Roszdravnadzor,…

03.17.2016
READ ARTICLE
new-img-8

Pharmaceuticals

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF”

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF” in which pills the metal wire was found.

05.18.2016
READ ARTICLE
new-img-9

Roszdravnadzor

Medical equipment stands idle in the Pskov region

Roszdravnadzor (RZN) statement: the expensive medical equipment for the total amount of 342 million rubles stands idle in…

05.19.2016
READ ARTICLE
new-img-10

Control

Hospital control Jewish autonomous region

Roszdravnadzor has audited the activity of the Regional Budgetary Public Health Facility “Central district hospital of Lenin”…

05.20.2016
READ ARTICLE